Genetic testing to predict response to mavacamten in hypertrophic cardiomyopathy
Part of Heart & circulation clinical trials.
This study looks at how a drug called mavacamten, which relaxes the heart muscle, works in people with obstructive hypertrophic cardiomyopathy. It uses genetic testing to try to predict who will respond best to the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a confirmed diagnosis of obstructive hypertrophic cardiomyopathy (a type of thickened heart muscle that blocks blood flow).
- The thickening must not be caused by other conditions like high blood pressure or heart valve disease.
- You cannot have a condition that mimics HCM, like amyloidosis or Fabry disease.
- You cannot have had septal reduction therapy (surgery or alcohol ablation) within the last 6 months.
- You cannot have a low heart pumping function (ejection fraction below 55%), uncontrolled heart failure, or be pregnant (or have other reasons you cannot take the study drug).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether mavacamten, a medication that may help the heart use energy better, can improve symptoms in people with obstructive hypertrophic cardiomyopathy. It aims to see if this drug helps with chest pain and shortness of breath, and improve overall heart function.
This trial tests if mavacamten can help people with hypertrophic cardiomyopathy (HCM) who have obstruction in the middle or tip of the heart (not the usual outflow tract). You may join if you have symptoms like chest pain or shortness of breath and a pressure gradient above 30 mmHg in these areas.
This study collects blood samples and medical information from people with obstructive hypertrophic cardiomyopathy to learn why the medication mavacamten works differently in different people. The goal is to understand how genes and other factors influence treatment response, which may help personalize care.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
This study looks at adults with a heart condition called obstructive hypertrophic cardiomyopathy. It tracks what happens after they start taking the medicine mavacamten, to learn more about its effects and how it works in real life.
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
Hear when a new Hypertrophic Cardiomyopathy (HCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.